Wczytywanie spółki
Just reported
Q3 2026 results
From Hims & Hers Health's results release of 9 listopada 2026; its quarterly report has since been filed.
Revenue
Actual
890,4M USD
+49% y/y
+18% q/qGuided
890M USD
midpoint
Within guide0,0%EPS, GAAP
Actual
-0,14 USD
Guided
—
No guide given
Operating income, GAAP
Actual
-66,1M USD
Guided
—
No guide given
Company outlook
Q4 2026
- Revenue875M USD – 895M USD+43% y/y First given
Full year 2026
- Revenue3,13B USD – 3,15B USD+34% y/y Lowered -1,9%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Hims & Hers Health is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Drug Manufacturers Specialty and Generic
Graded A or B and worth $2B or more: A first, then the largest.
TAKTakeda Pharmaceutical Company Limited34,4B USDA
NBIXNeurocrine Biosciences, Inc.16,9B USDA+
ELANElanco Animal Health Incorporated13,4B USDA
KNSAKiniksa Pharmaceuticals International, plc8,2B USDA+
LQDALiquidia Corporation5,2B USDA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 paź 2026CAGraded C, now A
Jak zarabia
- Sales to customers in the United States87%
- Sales to customers outside the United States13%
Udziały w przychodach to szacunki za quarter ended March 31, 2026, a nie dane z raportu złożonego do regulatora.
Konkuruje z
Co sprzedaje5
Prescription treatments
Medicines prescribed by clinicians for conditions including sexual health, hair loss, hormone health, weight loss, skin conditions, and mental health. Prescriptions may be filled by company-owned or partner pharmacies.
Weight-loss care and medicines
Weight-loss medicines, including access to branded medicines and, on a limited scale, compounded medicines, with a membership that can include ongoing clinician support.
Non-prescription products
Products such as skin care, hair care, sexual wellness products, cosmetics, and supplements, sold under Hims & Hers or co-branded with manufacturers.
Pokaż 2 więcej
Laboratory testing
Testing services that measure health markers and provide results to support health assessments and follow-up care with clinicians.
Telehealth consultations and follow-up care
Remote consultations with licensed healthcare professionals, who assess customers and may prescribe medication or provide ongoing care.
Kto to kupuje3
- Consumers who buy prescription treatments and related care directly through Hims & Hers websites and apps; many choose recurring subscriptions and are billed when products ship or services are provided.
- Consumers who make one-time purchases through the websites, apps, or retail stores.
- Retail partners that buy or sell Hims & Hers non-prescription products in stores and on third-party websites.
Na czym się opiera i co może to zburzyć
Od czego zależy ta działalność
- 1In the United States, clinical care depends on contractual relationships with independent affiliated medical groups, which retain control over medical decisions.
- 2Fulfilling prescriptions depends on licensed company-owned and partner pharmacies, product manufacturers, and suppliers.
- 3The business depends on access to the internet, cloud and payment providers, and systems that handle sensitive customer health information.
- 4Selling and fulfilling medicines, compounded drugs, and laboratory tests depends on healthcare, pharmacy, product-safety, and privacy rules in each market.
Co może pójść nie tak
- 1Regulators may restrict compounded medicines, including weight-loss drugs. The company received warning letters concerning promotion of compounded products, and the United States Food and Drug Administration said it intended to restrict certain ingredients for mass-marketed compounded drugs.
- 2Changes in telehealth and medical-practice rules could disrupt the company’s arrangements with affiliated medical groups or limit how clinicians assess patients and prescribe medicines.
- 3A data breach or failure to comply with changing privacy laws could expose sensitive health information, trigger penalties or lawsuits, and damage customer trust.
Pełne sprawozdania finansowe →
O spółce Hims & Hers Health, Inc.
Customers use Hims & Hers websites and apps to find treatments, answer health questions, and connect with licensed healthcare professionals. When appropriate, clinicians prescribe medication, which Hims & Hers or other licensed pharmacies ship to customers; customers can also buy non-prescription products and laboratory testing. In the United States, independent medical groups make clinical decisions, while Hims & Hers provides administrative and technology services. It had 2.891 million subscribers (June 30, 2026, high), meaning customers with recurring billing; monthly revenue per average subscriber was $92 (three months ended June 30, 2026, high), a measure that also includes revenue from one-time purchases.
- Siedziba
- San Francisco, California
- Rok założenia
- 2017
- Zatrudnienie
- 2,442 (December 31, 2025, high)
- Notowana na
- NYSE
- Koniec roku obrotowego
- December 31
Zbudowane z własnych raportów spółki Hims & Hers Health, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
